Subscription Center
Dec 8, 2008
An experimental malaria vaccine for babies reduced the chances of developing the mosquito-borne illness by more than half, scientists are reporting today. The results, from two trials conducted in Kenya and Tanzania, are the most promising yet in the quest to develop effective immunization against the life-threatening parasite.
The findings on GlaxoSmithKline's RTS,S/AS01 showed a 53 percent lower risk of infection over eight months and were presented today at the annual American Society for Tropical Medicine and Hygiene meeting in New Orleans. They build on results published last year that found that GSK's RTS,S/AS02 vaccine (the same shot formulated with a different adjuvant, or immune-enhancing additive) slashed the risk of a first-time malaria infection by 66 percent in infants who received the full three-dose course. A safety study on that vaccine published in today's online edition of the New England Journal of Medicine showed about the same efficacy — a 65 percent reduction in first-time infections for babies 12 months and younger.
See what we're tweeting about
johnrplatt The best thing about this weekend was seeing and hearing so many people laugh at my comics. (1/2)
Dhunterauthor Yes, Joseph Harker, whi… http://t.co/rDn8abAIeP
EricROlson The History of Typography - Animated Short http://t.co/p55PVlJXKO
Deadline: Jul 30 2013
Reward: $100,000 USD
The Seeker desires a method for producing pseudoephedrine products in such a way that it will be extremely difficult for clandestine che
Deadline: Jun 29 2013
Reward: $7,000 USD
The Seeker for this Challenge desires proposals for chemical methods that could rapidly degrade a dilute aqueous solution
Powered By: 
YES! Send me a free issue of Scientific American with no obligation to continue the subscription. If I like it, I will be billed for the one-year subscription.
